Researchers examined a new manifestation of primary hyperoxaluria that has rarely been described in previous literature and reviewed best approaches to managing dental complications in this patient...
Primary hyperoxaluria type 1 is a rare disease that is frequently diagnosed late due to its similar clinical presentation to other types of kidney disease. To better understand the characteristics of...
Individuals with primary hyperoxaluria type 1 are at an increased risk of urinary stone disease, nephrocalcinosis, and chronic kidney disease due to increased hepatic oxalate production. Researchers...
The once-monthly RNA interference injection medication received FDA approval based on results from the phase II PHYOX2 clinical trial and phase III PHYOX3 extension study.
In a randomized clinical trial, a team of researchers compared the use of cefepime and piperacillin-tazobactam—commonly used medications for empirical treatment of infection—to determine the risks of...
Did you watch our Multidisciplinary Roundtable on managing nutrition in patients with chronic kidney disease? Here are some highlights that you may have missed.
The FDA approves the first-of-its-kind treatment for anemia caused by CKD for adults who receive dialysis following the results of a randomized clinical trial.
The Work Group from the Kidney Disease: Improving Global Outcomes organization updated its set of guidelines that offers clinical practice guidelines in the treatment of chronic kidney disease and...
